A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

PHASE3CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Interventions

DRUG

tolvaptan

Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.

Trial Locations (7)

Chubu Region

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Tohoku Region